Stocks and Investing
Stocks and Investing
Fri, August 12, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, August 11, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Marc Goodman Maintained (XENE) at Buy with Increased Target to $46 on, Aug 11th, 2022
Marc Goodman of SVB Leerink, Maintained "Xenon Pharmaceuticals Inc." (XENE) at Buy with Increased Target from $40 to $46 on, Aug 11th, 2022.
Marc has made no other calls on XENE in the last 4 months.
There are 3 other peers that have a rating on XENE. Out of the 3 peers that are also analyzing XENE, 0 agree with Marc's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Marc
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $46 on, Wednesday, August 10th, 2022
- Tessa Romero of "JP Morgan" Initiated at Buy and Held Target at $55 on, Thursday, July 21st, 2022
- Laura Chico of "Wedbush" Maintained at Buy with Decreased Target to $41 on, Monday, June 27th, 2022
Contributing Sources